What You Should Know:
- COTA, a leading real-world data (RWD) and analytics company in oncology, has announced a new collaboration with Sanofi.
- The strategic partnership aims to leverage RWD and artificial intelligence (AI) to accelerate clinical trials specifically focused on multiple myeloma, a cancer affecting white blood cells. The findings from this partnership have the potential to significantly impact future clinical trial designs for multiple myeloma.
Unlocking
Read More
Sanofi
Sanofi & Flatiron Health Partner to Redesign Clinical Trial Experience for Sponsors
What You Should Know:
Flatiron Health announced a new partnership today with Sanofi in their pursuit to redesign the clinical trial experience for sponsors, sites, and patients in the therapeutic area of oncology. The multi-study partnership between Sanofi and Flatiron will focus on improving clinical trial data acquisition, delivery, and quality through site-facing technology that digitally transfers data captured in the electronic health record (EHR) directly into the electronic data
Read More
Accelerating Clinical Trials Through AI-Enabled Precision Oncology
The American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mortality rates and increased trial diversity. However, there is still much work to be done. Especially with the multiple types of new and ongoing challenges clinicians and staff members are facing - such as high turnover rates, decreased budgets and increased feelings of burnout - taking the necessary steps to enhance clinical trial procedures is crucial
Read More
Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients
What You Should Know:
- Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance. The price cut goes into effect January 1, 2024.
- The price cut milestone comes in addition to decisions taken in June 2022 to lower diabetes medicines costs: the launch of an unbranded Lantus biologic at -60% versus Lantus list price, and a cap on out-of-pocket costs on insulin to $35 for all people
Read More
Protai Raises $20M to Build an Oncology Drug Discovery Pipeline
What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B
What You Should Know:
- Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity value of approximately $2.9B.
- The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet
Read More
39 Organizations Sign Global Heath Equity Pledge to Advance Health Equity Globally
What You Should Know:
- Today, World Economic Forum announced that 39 organizations have signed the Global Health Equity Network Zero Health Gaps Pledge.
- The pledge includes 10 key commitments all signatories have made to embed health equity principles throughout their operations, workforce and guiding philosophies. It marks the beginning of an historic journey to making health equity an integral part of business strategies globally and an important step towards a world without health
Read More
COTA Appoints Noel Alaka as VP of Life Sciences
What You Should Know:
Today, oncology real-world data analytics company COTA announced the appointment of Noel Alaka as Vice President of Life Sciences.
As VP of Life Sciences, Alaka will be responsible for helping grow and build partnerships with leading life sciences companies that are looking to adopt real-world data and real-world evidence to help accelerate innovation in treatments for patients facing cancer.
Noel Alaka Bio/Background
A benchtop
Read More
Sanofi Taps Yseop to Accelerate Medical Writing and Reporting Processes
What You Should Know:
- Yseop, an artificial intelligence (AI) software company and pioneer in Natural Language Processing (NLP), today announced that Sanofi, the global healthcare company, has chosen to scale its natural language generation (NLG) capabilities with Yseop.
- Sanofi will use the platform to accelerate its clinical study submission processes and bring new treatments to patients faster.
- Sanofi plans to continue to expand the use of the Yseop
Read More
Sanofi Launches Its First Digital Health Accelerator to Address Unmet Patient Needs
What You Should Know:
- Sanofi launched its first Digital Accelerator to better leverage data and artificial intelligence to develop solutions that address unmet patient needs.
- The Digital Accelerator team is developing an integrated platform and data solution to enhance awareness of atopic dermatitis and available treatment options amongst patients and HCPs.
Digital Accelerator Focus
The Digital Accelerator is the next step in Sanofi’s
Read More
